Kratom & kava guides
Oxonol, MGM-15 and DEA Scheduling: August 2026 Status
MGM-15 is temporarily Schedule I under federal law. DEA's order took effect August 26, 2026 and remains in effect through August 26, 2028 unless extended or replaced sooner.
The order follows the compound
DEA names MGM-15 by chemical structure and also calls it dihydro-7-hydroxymitragynine. Oxonol, “advanced botanical,” “research product,” and other brand-style descriptions leave that legal identity unchanged.
What else the order covers
The same temporary order covers mitragynine pseudoindoxyl (MGPI) and MGM-16. DOJ describes limited enforcement discretion for incidental trace MGPI in an otherwise botanical kratom product while keeping MGPI in Schedule I. MGM-15 and MGM-16 fall outside that limited policy.
Why this is separate from the 7-OH threshold proposal
The three-compound order is already effective. DEA's other 2026 action proposes a threshold for 7-OH itself; HHS accepted comments through September 10, and the proposal remained pending on September 19. Keep the effective order and pending threshold action in separate status statements.
Read the active compound behind the name
- Find the exact active ingredient on the label and report.
- If it is MGM-15, treat the current federal Schedule I status as controlling.
- Replace undated “legal alternative” claims with the August 26 order.
- Check state law and other federal requirements separately.
Kratom Paradise does not sell Oxonol, MGM-15, MGPI, MGM-16, or synthetic or concentrated 7-OH. MIT products contain mitragynine.